These antibodies perform exceptionally well in the intended applications and have undergone stringent testing and additional validation to ensure monospecificity.
Trial Size Available
Carrier-Free Available

Formalin-fixed, paraffin-embedded human Ewing's Sarcoma stained with CD99 Rabbit Recombinant Monoclonal Antibody (MIC2/3478R).

Formalin-fixed, paraffin-embedded human Ewing's Sarcoma stained with CD99 Rabbit Recombinant Monoclonal Antibody (MIC2/3478R).
| Document Name | |
|---|---|
| Datasheet | Download Here |
| Material Safety Data Sheet | Download Here |
| Applications | Tested Dilutions | Protocol | Note |
|---|---|---|---|
| Immunohistochemistry (IHC) | 1-2ug/ml | IHC Protocol | 30 min at RT. Staining of formalin-fixed tissues requires heating tissue sections in 10mM Tris with 1mM EDTA, pH 9.0, for 45 min at 95°C followed by cooling at RT for 20 minutes |
| Western Blot (WB) | 2-4ug/ml | Western Blot Protocol |
CD99 is a type I transmembrane glycoprotein encoded by the CD99 gene and the functions of CD99 in cells in which CD99 was highly expressed have been studied and they were as follows: cell death of thymocytes and T lymphocytes, migration through monocyte endothelial junctions by adhesion and diapedesis, cell-cell adhesion in lymphocytes, maintenance of cellular morphology in Hodgkin and Reed/Sternberg cells, and recruitment of T cells.CD99 expression has been reported in many cell types, such as hematopoietic cells, endothelial cells, central nervous system ependymal cells, thymocytes, granular cells of the ovary, Sertoli cells, and pancreatic islet cells. And in tumors it expressed by virtually almost all Ewing s sarcoma and primitive peripheral neuroectodermal tumors (ES/PNET) and demonstrates strong and diffuse membranous staining. Other tumors that may show CD99 expression include neuroendocrine carcinomas, mesenchymal chondrosarcomas, solitary fibrous tumors, synovial sarcomas, vascular tumors, small round blue cell tumors, lymphoblastic lymphoma, acute myeloid leukemia, and myeloid sarcoma. Studies have shown that CD99 may be a sensitive marker for Ewing s sarcoma and peripheral neuroectodermal tumors.
Should a NeoBiotechnologies antibody not meet the experimental expectations outlined on our website or datasheet, please contact our Technical Support. We unconditionally guarantee our product.
Our team of scientists are ready to help you with expert recommendations or technical assistance related to applications or product use.
Information
© 2026 NeoBiotechnologies. All Rights Reserved.
Monday-Friday: 8:00am – 8:00pm Pacific Time